Pepgen reports third quarter 2022 financial results and recent corporate developments

Boston, nov. 10, 2022 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended september 30, 2022 and highlighted recent corporate developments.
PEPG Ratings Summary
PEPG Quant Ranking